DEF 14A: Fortrea Holdings Inc. Announces 2025 Annual Meeting of Stockholders, Outlines Key Proposals

Fortrea Holdings Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, to vote on director elections, auditor ratification, executive compensation, and an incentive plan amendment.

Summary

• Fortrea Holdings Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025.
• Stockholders of record as of April 17, 2025, are entitled to vote on several key proposals.
• The proposals include the election of three Class II Directors, ratification of Deloitte & Touche LLP as the independent accounting firm, an advisory vote on executive compensation, and approval of an amended and restated 2023 Omnibus Incentive Plan.
• The Board of Directors recommends voting 'FOR' all listed proposals.
• The company's common stock is listed on Nasdaq under the symbol FTRE.
• Fortrea is a leading global provider of clinical development solutions to the life sciences industry with approximately 15,500 employees in over 100 countries.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative information. While there are positive aspects such as backlog growth and strategic initiatives, the financial results were below expectations, and a restatement was required. The sentiment is neutral to slightly positive.

Positives

• The Board of Directors is actively engaged with stockholders and values their perspectives.
• The company has implemented a virtual-only meeting format to enhance shareholder access and participation.
• The proposed amendments to the 2023 Omnibus Incentive Plan include stockholder-favorable provisions, such as minimum vesting periods and restrictions on dividend payments for unvested awards.
• The company has a clawback policy in place to recover incentive-based compensation in the event of financial restatements or misconduct.

Negatives

• The company's Adjusted EBITDA for the full year 2024 was below its revised targeted range.
• The company had a net loss of $328.5 million for the fiscal year ending December 31, 2024.
• The company had to restate its 2023 financial results due to errors identified in connection with the preparation of its financial statements for the quarter ended March 31, 2024.

Risks

• The company's international operations could subject it to additional risks and expenses that could adversely impact its business or results of operations.
• The company faces cybersecurity risks that could disrupt its operations and compromise sensitive information.
• The company's success depends on its ability to contract with suitable investigators and recruit and enroll patients for clinical trials.
• The company's success depends on generating a large number of net new business awards, and delays, terminations, or reductions in scope could adversely affect its business.

Future Outlook

The company expects to continue executing major projects and transactions in 2025, focusing on its core CRO business and improving its cost structure.

Management Comments

• Thomas H. Pike, Chief Executive Officer and Chairman of the Board, expressed gratitude for stockholders' support and urged them to vote.
• Management noted improved sales momentum in the second half of 2024, achieving a target of more than 1.2x book-to-bill ratio.

Industry Context

The document notes greater competition across the CRO industry, driven by slowing pharmaceutical and biotechnology spending.

Comparison to Industry Standards

• The document references a peer group of seventeen companies used for benchmarking executive and non-employee director compensation levels.
• The peer group includes companies such as IQVIA Holdings, Inc., Charles River Laboratories International, Inc., and Medpace Holdings, Inc.
• The company compares its size and complexity of operations to those of the companies identified in the peer group.
• The company also compares the peer group's current executive compensation and compensation mix to its current practices.

Related Party Transactions

• The document mentions agreements with Labcorp, including a Transition Services Agreement, a Tax Matters Agreement, and an Employee Matters Agreement, to govern the ongoing relationships between the companies after the Spin.

Stakeholder Impact

• The document outlines potential impacts on shareholders through proposals related to director elections, executive compensation, and the incentive plan.
• The document outlines potential impacts on employees through proposals related to executive compensation and the incentive plan.

Next Steps

• Stockholders are urged to vote their shares via phone, internet, or mail.
• The company will announce preliminary voting results at the Annual Meeting and report final results in a Form 8-K filed with the SEC.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Incentive Plan, Fortrea, Governance, Voting, Deloitte